drugset / Trial / NCT00734188
Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, dose-escalation study to determine the safety, maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of 188Re-PTI-6D2 in patients with metastatic melanoma.
Timeline
- Start
- 2009-01
- Primary completion
- 2010-03
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PTI-6D2 | Unknown | — | Intravenous |